Inhibition of FKBP10 Attenuates Hypertrophic Scarring through Suppressing Fibroblast Activity and Extracellular Matrix Deposition
- 1 November 2017
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 137 (11) , 2326-2335
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- miR-145 Contributes to Hypertrophic Scarring of the Skin by Inducing Myofibroblast ActivityMolecular Medicine, 2015
- HSP47 and FKBP65 cooperate in the synthesis of type I procollagenHuman Molecular Genetics, 2014
- A Novel Murine Model of Hypertrophic Scarring Using Subcutaneous Infusion of BleomycinPlastic and Reconstructive Surgery, 2014
- Kuskokwim Syndrome, a Recessive Congenital Contracture Disorder, Extends the Phenotype ofFKBP10 MutationsHuman Mutation, 2013
- Absence ofFKBP10in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrixHuman Mutation, 2012
- Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment StrategiesMolecular Medicine, 2010
- Mutations in the Gene Encoding the RER Protein FKBP65 Cause Autosomal-Recessive Osteogenesis ImperfectaThe American Journal of Human Genetics, 2010
- Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injuryJournal of Hepatology, 2008
- Wound repair and regenerationNature, 2008
- Fibroblasts, myofibroblasts, and wound contractionJournal of Cell Biology, 1994